237 related articles for article (PubMed ID: 25891805)
1. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
3. Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom.
Earnshaw SR; McDade C; Bryan A; Ines M; Micallef C; Sung A; Enoch DA
Microbiol Spectr; 2022 Jun; 10(3):e0042522. PubMed ID: 35532266
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.
Turner SJ; Senol E; Kara A; Al-Badriyeh D; Kong DC; Dinleyici EC
Int J Antimicrob Agents; 2013 Sep; 42(3):276-80. PubMed ID: 23830892
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.
Naik S; Lundberg J; Kumar R; Sjolin J; Jansen JP
Scand J Infect Dis; 2011 Jul; 43(6-7):504-14. PubMed ID: 21332286
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
Bagshaw E; Enoch DA; Blackney M; Posthumus J; Kuessner D
Future Microbiol; 2018 Sep; 13(11):1283-1293. PubMed ID: 29911889
[TBL] [Abstract][Full Text] [Related]
12. Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt.
Kaci Z; Shalaby L; Kamal S; Boudjerra N; Gao X; Xue M; Ait Belkacem S; Gab Allah Ibrahim A; Kotb R; Charbonneau C
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):693-700. PubMed ID: 31055986
[No Abstract] [Full Text] [Related]
13. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
14. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
[TBL] [Abstract][Full Text] [Related]
15. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
Ostermann H; Solano C; Jarque I; Garcia-Vidal C; Gao X; Barrueta JA; De Salas-Cansado M; Stephens J; Xue M; Weber B; Charbonneau C
BMC Pharmacol Toxicol; 2014 Sep; 15():52. PubMed ID: 25253630
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
Kaskel P; Tuschy S; Wagner A; Bannert C; Cornely OA; Glasmacher A; Lipp HP; Ullmann AJ
Ann Hematol; 2008 Apr; 87(4):311-9. PubMed ID: 17929018
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
[TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
